The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit
later.
We apologize for any inconvenience caused
The efficacy analysis of interferon combined with imatinib in chronic myelogenous leukemia patients with ABL kinase domain mutations
Author(s): ZU Zuoling, ZHANG Zuoli, ZHOU Jian, ZHAO Huifang, GUI Ruirui, LI Zhen, GAO Songkun, SONG Yongping
Pages: 794-
796
Year: 2016
Issue:
10
Journal: Chinese Journal of Internal Medicine
Keyword: Leukemia; myeloid; chronic-phase; Mutation; ABL kinase domain;
Abstract: To retrospectively analyze the efficacy of interferon plus imatinib (IM) in patients with chronic-phase chronic myelogenous leukemia (CML-CP) and ABL kinase domain mutations.The mutation rates of ABL kinase region in patients with Sokal score low,medium and high risk CML-CP were statistically significant (6.25%,9.42% and 47.06%,P <0.05).The response rates of interferon plus IM versus second-generation TKI in CML-CP with non-T315I ABL kinase domain mutations were comparable (61.11%vs 65.52%,P > 0.05).When CML-CP patients with ABL kinase domain mutations were resistant to TKI or not accessible to second-generation TKI,interferon plus IM can be an alternative choice.
Citations
No citation found
Related Articles
No related articles found